<div id="readability-page-1"><p>Moody Lynn &amp; Lieberson LLC boosted its position in  AbbVie Inc. (NYSE:ABBV - Free Report) by 6.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 183,462 shares of the company's stock after buying an additional 11,085 shares during the period. AbbVie makes up   2.3% of Moody Lynn &amp; Lieberson LLC's holdings, making the stock its 14th biggest holding. Moody Lynn &amp; Lieberson LLC's holdings in AbbVie were worth $42,479,000 at the end of the most recent quarter.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>A number of other large investors have also recently bought and sold shares of the business. Marshall &amp; Sullivan Inc. WA acquired a new position in  AbbVie in the second quarter valued at approximately $25,000.  Evolution Wealth Management Inc. bought a new stake in shares of  AbbVie in the 2nd quarter valued at $26,000.  Spurstone Advisory Services LLC bought a new stake in shares of  AbbVie in the 2nd quarter valued at $28,000.  Financial Gravity Companies Inc. acquired a new position in shares of  AbbVie during the 2nd quarter valued at $36,000.  Finally, Delos Wealth Advisors LLC bought a new position in  AbbVie during the second quarter worth $39,000. 70.23% of the stock is currently owned by institutional investors and hedge funds. </p><h2>AbbVie Trading Down 0.5%</h2><p>NYSE ABBV opened at $228.55 on Thursday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The business has a fifty day simple moving average of $226.67 and a 200 day simple moving average of $213.37. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $403.94 billion, a P/E ratio of 173.14, a PEG ratio of 1.30 and a beta of 0.36. </p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  On average, analysts predict that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a positive change from AbbVie's previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie's dividend payout ratio (DPR) is 496.97%. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>ABBV has been the topic of several research reports. JPMorgan Chase &amp; Co. upped their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, November 3rd. Hsbc Global Res raised AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Wednesday, December 10th. Cantor Fitzgerald  set a $250.00 price objective on AbbVie and gave the company an &#34;overweight&#34; rating in a research note on Thursday, October 9th. Citigroup lowered their target price on AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating on the stock in a research report on Monday, November 3rd. Finally, Erste Group Bank cut AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued  a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $245.84.</p><p><b>View Our Latest Report on AbbVie</b></p><h2>About AbbVie</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than AbbVie</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Moody Lynn & Lieberson LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 6.4% in Q3, owning 183,462 shares valued at $42.48 million. AbbVie represents 2.3% of the firm's portfolio. The company reported $1.86 EPS for the last quarter, exceeding estimates, with revenue of $15.78 billion. AbbVie announced a quarterly dividend of $1.73, up from $1.64, with a yield of 3.0%. Analysts have mixed ratings on the stock, with an average target price of $245.84.</p>

Moody Lynn & Lieberson LLC Has $42.48 Million Holdings in AbbVie Inc. $ABBV